PD-1 inhibitor combined with chemotherapy in the treatment of metastatic nasopharyngeal carcinoma: a case report

Published on May. 29, 2024Total Views: 1278 times Total Downloads: 580 times Download Mobile

Author: CHENG Yanshuang ¹ WANG Juan ¹ JIN Jieying ¹  WU Qiuji ²  ZHONG Yahua ¹

Affiliation: 1. Department of Head, Neck and Pediatric Oncology Radiotherapy and Chemotherapy, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 2. Department of Gynecological Oncology Radiotherapy and Chemotherapy, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Keywords: Nasopharyngeal carcinoma PD-1 inhibitor Immunotherapy Chemotherapy

DOI: 10.12173/j.issn.1004-4337.202403024

Reference: Cheng YS, Wang J, Jin JY, Wu QJ, Zhong YH. PD-1 inhibitor combined with chemotherapy in the treatment of metastatic nasopharyngeal carcinoma: a case report[J]. Journal of Mathematical Medicine, 2024, 37(5): 392-397. DOI: 10.12173/j.issn.1004-4337.202403024[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

This paper retrospectively analyzed the diagnosis and treatment process of a patient with advanced nasopharyngeal carcinoma (NPC) accompanied by multiple liver, lung, and lymph node metastases. The patient underwent camrelizumab immunotherapy in conjunction with chemotherapy, and demonstrated positive efficacy with a progression-free survival of 55 months. Despite a 5-month interruption in immunotherapy treatment caused by the COVID-19 epidemic, the patient's tumor remained well controlled with no apparent signs of recurrence or metastasis. Throughout the treatment, there were no grade 3-4 treatment-related side effects, and the patient's quality of life remained good. Immunotherapy combined with chemotherapy can bring significant survival benefits to patients with the recurrent/metastatic NPC.

Full-text

Please download the PDF version to read the full text: download

References

1.Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

2.Wu F, Wang R, Lu H, et al. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study[J]. Radiother Oncol, 2014, 112(1): 106-111. DOI: 10.1016/j.radonc.2014.05.005.

3.Jia GD, Sun XS, Li XY, et al. Clinical characteristics and prognostic factors affecting survival after radical radiotherapy for early and late post-treatment metastatic nasopharyngeal carcinoma[J]. BMC Cancer, 2023, 23(1): 7. DOI: 10.1186/s12885-022-10494-7.

4.Tang LL, Chen YP, Chen CB, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma[J]. Cancer Commun (Lond), 2021, 41(11): 1195-1227. DOI: 10.1002/cac2.12218.

5.Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026.

6.Teo PM, Kwan WH, Lee WY, et al. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma[J]. Cancer, 1996, 77(12): 2423-2431. DOI: 10.1002/(SICI)1097-0142(19960615)77:12< 2423::AID-CNCR2>3.0.CO;2-N.

7.Lu TZ, Zeng FJ, Hu YJ, et al. Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma[J]. Cancer Med, 2023, 12(24): 22091-22102. DOI: 10.1002/cam4.6816.

8.Prawira A, Oosting SF, Chen TW, et al. Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review[J]. Br J Cancer, 2017, 117(12): 1743-1752. DOI: 10.1038/bjc.2017.357.

9.Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018, 19(10): 1338-1350. DOI: 10.1016/s1470-2045(18)30495-9.

10.Xu JY, Wei XL, Wang YQ, et al. Current status and advances of immunotherapy in nasopharyngeal carcinoma[J/ OL]. Ther Adv Med Oncol, 2022, 14: 17588359221096214. DOI: 10.1177/ 17588359221096214.

11.Fang W, Zhang J, Hong S, et al. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy[J]. Oncotarget, 2014, 5(23): 12189-12202. DOI: 10.18632/oncotarget.2608.

12.Silva JM, Alves CEC ,Pontes GS. Epstein-Barr virus: the mastermind of immune chaos[J]. Front Immunol, 2024, 15: 1297994. DOI: 10.3389/fimmu.2024.1297994.

13.Wang J, Ge J, Wang Y, et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1[J]. Nat Commun, 2022, 13(1): 866. DOI: 10.1038/s41467-022-28479-2.

14.Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192): 64-80. DOI: 10.1016/s0140-6736(19)30956-0.

15.Grasselly C, Denis M, Bourguignon A, et al. The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent[J]. Front Immunol, 2018, 9: 2100. DOI: 10.3389/fimmu.2018. 02100.

16.Principe DR, Kamath SD, Korc M, et al. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy[J]. Pharmacol Ther, 2022, 236: 108111. DOI: 10.1016/j.pharmthera.2022.108111.

17.Fournel L, Wu Z, Stadler N, et al. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer[J]. Cancer Lett, 2019, 464: 5-14. DOI: 10.1016/j.canlet.2019.08.005.

18.Ng HY, Li J, Tao L, et al. Chemotherapeutic treatments increase PD-L1 expression in esophageal squamous cell carcinoma through EGFR/ERK activation[J]. Transl Oncol, 2018, 11(6): 1323-1333. DOI: 10.1016/j.tranon.2018.08.005.

19.Tran L, Allen CT, Xiao R, et al. Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma[J]. Cancer Immunol Res, 2017, 5(12): 1141-1151. DOI: 10.1158/2326-6066.Cir-17-0235.

20.van der Most RG, Currie AJ, Mahendran S, et al. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy[J]. Cancer Immunol Immunother, 2009, 58(8): 1219-1228. DOI: 10.1007/s00262-008-0628-9.

21.Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2021, 22(8): 1162-1174. DOI: 10.1016/s1470-2045(21)00302-8.

22.Yang Y, Pan J, Wang H, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309)[J]. Cancer Cell, 2023, 41(6): 1061-1072. DOI: 10.1016/j.ccell.2023.04.014.

23.Mai HQ, Chen QY, Chen D, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial[J]. JAMA, 2023, 330(20): 1961-1970. DOI: 10.1001/jama.2023.20181.

24.Manako T, Yasumatsu R, Nakano T, et al. Immune checkpoint inhibitors for nasopharyngeal carcinoma in a real-world setting in Japan[J]. In Vivo, 2023, 37(2): 747-755. DOI: 10.21873/invivo.13137.

25.Lim DW, Kao HF, Suteja L, et al. Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma[J]. Nat Commun, 2023, 14(1): 2781. DOI: 10.1038/s41467-023-38407-7.